Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Assets (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Non-Current Assets for 7 consecutive years, with $138.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 30.39% to $138.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $651.5 million through Dec 2025, down 1.75% year-over-year, with the annual reading at $138.3 million for FY2025, 30.39% down from the prior year.
  • Non-Current Assets hit $138.3 million in Q4 2025 for BridgeBio Pharma, down from $158.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $220.4 million in Q3 2024 to a low of $65.9 million in Q1 2024.
  • Historically, Non-Current Assets has averaged $126.4 million across 5 years, with a median of $131.1 million in 2021.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 296.41% in 2021 and later plummeted 47.0% in 2022.
  • Year by year, Non-Current Assets stood at $123.9 million in 2021, then tumbled by 40.14% to $74.2 million in 2022, then fell by 7.27% to $68.8 million in 2023, then soared by 188.78% to $198.6 million in 2024, then crashed by 30.39% to $138.3 million in 2025.
  • Business Quant data shows Non-Current Assets for BBIO at $138.3 million in Q4 2025, $158.9 million in Q3 2025, and $167.9 million in Q2 2025.